Exploring the Full Potential of Risk-Sharing Agreements Between Pharma Companies and Payors
Health systems, health insurance companies, and other payors around the world are trying to strike the right balance between containing costs and giving patients access to innovative therapies. In doing so, they are putting the traditional pharmaceutical pricing model under intense pressure. Overall health care cost inflation, increasing market-access restrictions, and the growing use of cost-effectiveness assessments make it highly likely that the use of risk-sharing agreements will rise. Pharmaceutical companies that take an integrated approach to risk sharing can design deals that create benefits for themselves and payors.
Olivier Leclerc, Mandy Leung, and Heather Sumner
Health systems, health insurance companies, and other payors around the world are trying to strike the right balance between containing costs and giving patients access to innovative therapies. In doing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
